Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276067 | 0.97 | CNR2 (0.40) | CNR2ADORA3ADORA2AADORA1 | |
| SCHEMBL6275403 | 0.95 | CNR2 (0.40) | CNR2CYP2A6PTGESALOX5PPARG | |
| SCHEMBL6277737 | 0.94 | CNR2 (0.39) | CNR2ADORA3ADORA2AADORA1CYP2A6 | |
| SCHEMBL6276941 | 0.87 | CNR2 (0.38) | CNR2 | |
| SCHEMBL6270768 | 0.85 | CNR2 (0.47) | CNR2ADORA3ADORA2AADORA1CYP2A6 | |
| SCHEMBL6271304 | 0.85 | NQO1 (0.39) | CNR2CYP2A6ALOX5 | |
| SCHEMBL6276278 | 0.84 | CNR2 (0.38) | CNR2 | |
| SCHEMBL6277223 | 0.84 | CNR2 (0.39) | CNR2ADORA3ADORA2AADORA1CYP2A6 | |
| SCHEMBL6270575 | 0.84 | CNR2 (0.43) | CNR2ADORA3ADORA2AADORA1ALOX5 | |
| SCHEMBL6276043 | 0.83 | CNR2 (0.43) | CNR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273578-B1 | Benzopyran derivatives and antiallergic agent containing the same | DAINIPPON INK & CHEMICALS (JP) | 2005-02-23 | — | — | EP | disclosed |
| US-6670391-B2 | For inhibiting both immediate and delayed type allergic reactions; side effect reduction | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-12-30 | — | — | US | disclosed |
| US-20030096860-A1 | Benzopyran derivative and antiallergic agent | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1273578-A1 | Benzopyran derivatives and antiallergic agent containing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096860-A1 | Benzopyran derivative and antiallergic agent | HRH2, HRH1, HRH4 | CNR2 249/4885ADORA3 560/4885ADORA2A 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.